Updated

Researchers published some of the first human data suggesting that psychedelics like psilocybin can lower inflammation and offer protective effects for neurodegenerative diseases, NPR Health reported on October 21, 2026. Lab studies had previously shown that psychedelics could reduce inflammation, but the new human data signals this therapeutic potential holds promise for patients with conditions like Parkinson's disease.